Spain Drives Bentley
Executive Summary
Spain's patent situation has allowed Bentley Pharmaceuticals to thrive there by marketing both traditional generics and copies of patented products. But this Spanish loophole won't last forever.
You may also be interested in...
Esteve: Aspiring to Innovation
Changing global dynamics, and increasing price pressures in Spain, are compelling private Esteve to change its strategy and its structure. The company feels a need to be bolder and more efficient than before. The firm continues leveraging its traditional strength, helping Big Pharmas market. But lately it has also allied with US biotechs, paying more for exclusive rights to novel products. It's risky, though: two drug candidates it hoped to get failed recently. Now, making research pay off is a top priority for Esteve, which views itself as having a research-oriented culture, although its only successful drug was launched 20 years ago. The company's new strategy heightens risks and difficulties, but the owners feel they have little choice in the increasingly cost-controlled Spanish market. As a private company, Esteve can afford to place the bet and strive for success.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.